Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be
US biotech Moderna has chosen the location of its promised new R&D facility in the UK, selecting the Harwell Science Campus in Oxfordshire to site the unit.
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough